Pulmonary Arterial Hypertension Global Market Report 2022 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 175 | Published : May 2022 | SKU CODE : | Delivery Time: 2-3 business days | Format :


The pulmonary arterial hypertension market consists of sales of drugs by entities (organizations, sole proprietors, partnerships) that are used in the treatment of pulmonary arterial hypertension disease, which is a rare progressive disorder characterized by high blood pressure in the arteries of lungs. During this medical condition walls of the pulmonary arteries thicken and stiffen, making it difficult for the blood to flow through the lungs. The pulmonary arterial hypertension drugs relax the muscles in the wall of the blood vessels or increase the blood flow through the lungs or reverse the effect of the substance in the walls of blood vessels, which caused them to narrow.

The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/ subcutaneous. inhalational modes and distributed through retail and online channels.

The global pulmonary arterial hypertension market is expected to grow from $6.59 billion in 2021 to $7.04 billion in 2022 at a compound annual growth rate (CAGR) of 6.85%. The pulmonary arterial hypertension market is expected to reach $9.65 billion in 2026 at a CAGR of 8.22%.

The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published in National Organization for Rare Disorders, Inc., the new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500-1000 new cases each year, and Europe is expected to have similar incidence rates.

Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drugs sector are focusing on developing new medicines to improvise and cure the diseases. In March 2019, Sandoz, a Switzerland-based company specializing in high-quality affordable medications announced the first fully substitutable AP-rated generic version of Remodulin treprostinil injection in the USA sold by United Therapeutics Corporation. Treprostinil Injection is used to reduce the symptoms of Pulmonary Arterial Hypertension and has the same active ingredient, strengths, dose form, and inactive ingredients as Remodulin® (treprostinil), and it is provided to patients and clinicians with the same level of service and support but at a lower cost.

In September 2021, Merck Group a German-based multinational science and technology company that specializes in healthcare and life sciences solutions acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension.

Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc, Natco Pharma Ltd, Zydus Pharmaceutical USA, and Liquidia Technologies Inc.

North America was the largest region in the pulmonary arterial hypertension market in 2021. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global pulmonary arterial hypertension market is segmented -

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators

2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational

3) By Distribution channel: Retail, Online

    Table Of Contents

    1. Executive Summary

    2. Pulmonary Arterial Hypertension Market Characteristics

    3. Pulmonary Arterial Hypertension Market Trends And Strategies

    4. Impact Of COVID-19 On Pulmonary Arterial Hypertension

    5. Pulmonary Arterial Hypertension Market Size And Growth

    5.1. Global Pulmonary Arterial Hypertension Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Pulmonary Arterial Hypertension Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Pulmonary Arterial Hypertension Market Segmentation

    6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Endothelin Receptor Antagonists (ERAs)

    PDE-5 Inhibitors

    Prostacyclin and Prostacyclin Analogs

    SGC Stimulators

    6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oral

    Intravenous/ subcutaneous

    Inhalational

    6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Retail

    Online

    7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

    7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Pulmonary Arterial Hypertension Market

    8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Pulmonary Arterial Hypertension Market

    9.1. China Pulmonary Arterial Hypertension Market Overview

    9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Pulmonary Arterial Hypertension Market

    10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Pulmonary Arterial Hypertension Market

    11.1. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Pulmonary Arterial Hypertension Market

    12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Pulmonary Arterial Hypertension Market

    13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Pulmonary Arterial Hypertension Market

    14.1. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Pulmonary Arterial Hypertension Market

    15.1. Western Europe Pulmonary Arterial Hypertension Market Overview

    15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Pulmonary Arterial Hypertension Market

    16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Pulmonary Arterial Hypertension Market

    17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Pulmonary Arterial Hypertension Market

    18.4. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Pulmonary Arterial Hypertension Market

    19.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview

    19.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Pulmonary Arterial Hypertension Market

    20.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Pulmonary Arterial Hypertension Market

    21.1. North America Pulmonary Arterial Hypertension Market Overview

    21.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Pulmonary Arterial Hypertension Market

    22.1. USA Pulmonary Arterial Hypertension Market Overview

    22.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Pulmonary Arterial Hypertension Market

    23.1. South America Pulmonary Arterial Hypertension Market Overview

    23.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Pulmonary Arterial Hypertension Market

    24.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Pulmonary Arterial Hypertension Market

    25.1. Middle East Pulmonary Arterial Hypertension Market Overview

    25.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Pulmonary Arterial Hypertension Market

    26.1. Africa Pulmonary Arterial Hypertension Market Overview

    26.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

    27.1. Pulmonary Arterial Hypertension Market Competitive Landscape

    27.2. Pulmonary Arterial Hypertension Market Company Profiles

    27.2.1. United Therapeutics Corporation

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Bayer AG

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Gilead Sciences Inc.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Johnson & Johnson

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. GlaxoSmithKline

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

    29. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: United Therapeutics Corporation Financial Performance
  • Table 47: Bayer AG Financial Performance
  • Table 48: Gilead Sciences Inc. Financial Performance
  • Table 49: Johnson & Johnson Financial Performance
  • Table 50: GlaxoSmithKline Financial Performance

List Of Figures

Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Anti-Hypertensive Drugs Global Market Report 2022 – By Therapeutics (Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators), By Disease Source (Primary Hypertension, Secondary Hypertension), By End Users (Hospitals, Clinics, Homecare) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cardiovascular Medical Lasers Global Market Report 2022 – By Type (Excimer Laser, Carbon Dioxide Laser), By Application (Laser Vascular Anastomosis, Transmyocardial Laser Revascularization, Laser Angioplasty For Peripheral Arterial Diseases), By End Use (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Bioabsorbable Stents Global Market Report 2022 – By Product Type (Polymer-Based Bioabsorbable Stents, Metal-Based Bioabsorbable Stents), By End Use (Hospital, Homecare), By Absorption Rate (Slow- Absorption Stents, Fast- Absorption Stents), By Applications (Coronary Artery Diseases, Peripheral Artery Diseases) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Vascular Grafts Global Market Report 2022 – By Product (Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft), By Raw Material (Polyester Grafts, ePTFE, Polyurethane Grafts, Biosynthetic Grafts), By Application (Coronary Artery Disease, Aneurysm, Vascular Occlusion, Renal Failure), By End-User (Hospitals, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Wearable ECG Monitors Global Market Report 2022 – By Type (Wired, Wireless), By Application (Atrial fibrillation, Angina, Atherosclerosis, Cardiac dysrhythmia, Congestive heart failures (CHF), Coronary artery disease, Heart attack, Bradycardia, Tachycardia), By Grade (Consumer, Clinical), By Sales Channel (Online, Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2022 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests), By Disease Type (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis), By End-User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Anticoagulants Global Market Report 2022 – By Drug Class (Factor Xa Inhibitor, Heparin And LMWH, Vitamin K Antagonist), By Route Of Administration (Oral Anticoagulant, Injectable Anticoagulant), By Distribution Channel ( Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Venous Thromboembolism, Atrial Fibrillation Or Flutter, Coronary Artery Disease ), By End User (Hospitals, Homecare, Specialty Centers )– Market Size, Trends, And Global Forecast 2022-2026
View Report
Pulmonologists Global Market Report 2020 - By Practice (Owner-Solo Practice, Owner - Group Practice, Partner), By Disease (Chronic Obstructive Pulmonary Disease , Obstructive Sleep Apnea, Pulmonary Hypertension, Tuberculosis, Asthma And Allergy, Interstitial Lung Disease, Pneumonia, Lung Cancer, Cardio Pulmonary Disorders), COVID-19 Implications And Growth
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)